Tytuł pozycji:
304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial
-
Tytuł:
-
304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial
-
Autorzy:
-
Frenel, J-S.
Dalenc, F.
Pistilli, B.
de La Motte Rouge, T.
Levy, C.
Mouret-Reynier, M-A.
Hardy-Bessard, A-C.
Bonichon-Lamichhane, N.
Greilsamer, C.
Delecroix, V.
Nguyen, S.
Berger, F.
Everhard, S.
Lemonnier, J.
Loirat, D.
Callens, C.
Pradines, A.
Bachelot, T.
Delaloge, S.
Bidard, F.C.
-
Źródło:
-
In Annals of Oncology September 2020 31 Supplement 4:S364-S364
-